Combinatorial Drug Therapy for Cancers
JHU REF: [C12345]
Invention novelty: a combinatorial drug therapy for leukemia, ovarian, breast and lung cancers by targeting both epigenetic and DNA repair pathways.
Value Proposition
Conventional forms of cancer drug therapy are limited in their results once the cancers exhibit resistance to existing drug regimens. Thus, novel, effective therapies are needed to for continuous treatment of these cancers. This invention provides a new therapeutic approach to treat multiple forms of cancer, including leukemia, ovarian, breast and lung cancers. Advantages of the technology include:
- enhanced treatment options by using multiple combinations of drug regimens targeting both pathways
- synergistic activity from combinatorial drug therapy
- potential improved clinical outcomes compared to conventional forms of cancer drug therapy
Technical Details
Researchers from the Johns Hopkins University and the University of Maryland developed a new therapeutic approach to treating cancer by targeting both epigenetic and DNA repair pathways. This combinatorial drug therapy provides a synergistic effect, causing reduction in cancer colony growth in multiple cancer cell lines, including leukemia, ovarian, breast and lung cancers. Consecutive applications of both drugs to these cell lines targeting the concerned pathways significantly reduce colony growth even further than using either drug alone.
Looking for Partners: To develop & commercialize the technology as cancer therapeutics.
Stage of Development: Pre-Clinical
Data Availability: Under CDA / NDA
Patent Status: Pending
Publication(s)/Associated Cases: WO 2015/112598
Categories: Therapeutics
Keywords: leukemia, ovarian cancer, breast cancer, lung cancer, epigenetics
| Title |
App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
Patent Status |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
France |
15740207.4 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
Germany |
60 2015 056 142.2 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
Italy |
15740207.4 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
Spain |
15740207.4 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
United Kingdom |
15740207.4 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors |
PCT: Patent Cooperation Treaty |
European Patent Office |
15740207.4 |
3102199 |
1/21/2015 |
7/22/2020 |
1/21/2035 |
Granted |
| Therapy Regimen and Methods to Sensitize Cancer Cells Treated with Epigenetic Therapy to PARP Inhibitors in Multiple Cancers |
PCT: Patent Cooperation Treaty |
United States |
15/112,768 |
10,363,264 |
7/20/2016 |
7/30/2019 |
8/12/2035 |
Granted |
| Therapy Regimen and Methods to Sensitize Cancer Cells Treated with Epigenetic Therapy to PARP Inhibitors in Lung Cancer |
CON: Continuation |
United States |
15/254,738 |
10,105,383 |
9/1/2016 |
10/23/2018 |
9/9/2035 |
Granted |
| Therapy Regimen and Methods to Sensitize Cancer Cells Treated with Epigenetic Therapy to PARP Inhibitors in Ovarian Cancer |
CON: Continuation |
United States |
15/254,716 |
10,105,382 |
9/1/2016 |
10/23/2018 |
8/30/2035 |
Granted |
